| Literature DB >> 29366522 |
Hamidreza Aboulkheyr Es1, Leila Montazeri2, Amir Reza Aref3, Massoud Vosough1, Hossein Baharvand4.
Abstract
Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in more accurate predictions of drug responses in patients. Tumor organoid models have several advantages over pre-existing models, including conserving the molecular and cellular composition of the original tumor. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly preclinical drug screening and predicting patient responses to selected treatment regimens. Here, we highlight the advantages, challenges, and translational potential of tumor organoids in personalized cancer therapy and focus on gene-drug associations, drug response prediction, and treatment selection. Finally, we discuss how microfluidic technology can contribute to immunotherapy drug screening in tumor organoids.Entities:
Keywords: microfluidic technology; organoids; personalized cancer medicine; tumor modeling
Mesh:
Year: 2018 PMID: 29366522 DOI: 10.1016/j.tibtech.2017.12.005
Source DB: PubMed Journal: Trends Biotechnol ISSN: 0167-7799 Impact factor: 19.536